Insmed Incorporated (LON:0JAV)

Insmed Statistics

Total Valuation

Insmed has a market cap or net worth of GBP 30.79 billion. The enterprise value is 30.07 billion.

Market Cap	30.79B
Enterprise Value	30.07B

Important Dates

The last earnings date was Thursday, October 30, 2025.

Earnings Date	Oct 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	213.27M
Shares Outstanding	n/a
Shares Change (YoY)	+22.43%
Shares Change (QoQ)	+11.86%
Owned by Insiders (%)	0.69%
Owned by Institutions (%)	90.56%
Float	192.37M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	92.58
PB Ratio	43.77
P/TBV Ratio	55.24
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-34.15
EV / Sales	88.36
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-44.61

Financial Position

The company has a current ratio of 4.63, with a Debt / Equity ratio of 0.78.

Current Ratio	4.63
Quick Ratio	4.18
Debt / Equity	0.78
Debt / EBITDA	n/a
Debt / FCF	-0.82
Interest Coverage	-11.81

Financial Efficiency

Return on equity (ROE) is -165.69% and return on invested capital (ROIC) is -37.18%.

Return on Equity (ROE)	-165.69%
Return on Assets (ROA)	-28.05%
Return on Invested Capital (ROIC)	-37.18%
Return on Capital Employed (ROCE)	-50.95%
Revenue Per Employee	261,650
Profits Per Employee	-692,922
Employee Count	1,271
Asset Turnover	0.20
Inventory Turnover	0.96

Taxes

In the past 12 months, Insmed has paid 3.53 million in taxes.

Income Tax	3.53M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +168.07% in the last 52 weeks. The beta is 1.03, so Insmed's price volatility has been similar to the market average.

Beta (5Y)	1.03
52-Week Price Change	+168.07%
50-Day Moving Average	151.40
200-Day Moving Average	101.46
Relative Strength Index (RSI)	76.27
Average Volume (20 Days)	5,855

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.85

Income Statement

In the last 12 months, Insmed had revenue of GBP 332.56 million and -880.70 million in losses. Loss per share was -4.63.

Revenue	332.56M
Gross Profit	254.54M
Operating Income	-736.71M
Pretax Income	-877.18M
Net Income	-880.70M
EBITDA	-728.16M
EBIT	-736.71M
Loss Per Share	-4.63

Balance Sheet

The company has 1.25 billion in cash and 550.62 million in debt, giving a net cash position of 699.19 million.

Cash & Cash Equivalents	1.25B
Total Debt	550.62M
Net Cash	699.19M
Net Cash Per Share	n/a
Equity (Book Value)	703.45M
Book Value Per Share	3.31
Working Capital	1.13B

Cash Flow

In the last 12 months, operating cash flow was -657.19 million and capital expenditures -16.92 million, giving a free cash flow of -674.11 million.

Operating Cash Flow	-657.19M
Capital Expenditures	-16.92M
Free Cash Flow	-674.11M
FCF Per Share	n/a

Margins

Gross margin is 76.54%, with operating and profit margins of -221.53% and -264.83%.

Gross Margin	76.54%
Operating Margin	-221.53%
Pretax Margin	-263.77%
Profit Margin	-264.83%
EBITDA Margin	-218.96%
EBIT Margin	-221.53%
FCF Margin	n/a

Dividends & Yields

Insmed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.43%
Shareholder Yield	-22.43%
Earnings Yield	-2.86%
FCF Yield	-2.19%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Insmed has an Altman Z-Score of 3.4 and a Piotroski F-Score of 2.

Altman Z-Score	3.4
Piotroski F-Score	2